Acyl pyrazole sulfonamides as new antidiabetic agents: synthesis, glucosidase inhibition studies, and molecular docking analysis

Abstract

Diabetes mellitus is a multi-systematic chronic metabolic disorder and life-threatening disease resulting from impaired glucose homeostasis. The inhibition of glucosidase, particularly α-glucosidase, could serve as an effective methodology in treating diabetes. Attributed to the catalytic function of glucosidase, the present research focuses on the synthesis of sulfonamide-based acyl pyrazoles (5a-k) followed by their in vitro and in silico screening against α-glucosidase. The envisaged structures of prepared compounds were confirmed through NMR and FTIR spectroscopy and mass spectrometry. All compounds were found to be more potent against α-glucosidase than the standard drug, acarbose (IC50 = 35.1 ± 0.14 µM), with IC50 values ranging from 1.13 to 28.27 µM. However, compound 5a displayed the highest anti-diabetic activity (IC50 = 1.13 ± 0.06 µM). Furthermore, in silico studies revealed the intermolecular interactions of most potent compounds (5a and 5b), with active site residues reflecting the importance of pyrazole and sulfonamide moieties. This interaction pattern clearly manifests various structure–activity relationships, while the docking results correspond to the IC50 values of tested compounds. Hence, recent investigation reveals the medicinal significance of sulfonamide-clubbed pyrazole derivatives as prospective therapeutic candidates for treating type 2 diabetes mellitus (T2DM).

Reactivity of 2‐((3‐Cyano‐4‐(4‐Fluorophenyl)‐6‐(Naphthalen‐2‐yl)Pyridin‐2‐yl)Oxy)Acetohydrazide Toward Some Reagents for Preparing a Promising Anticancer Agents and Molecular Docking Study

“…Notably, Crizotinib, a pyrazole-based anticancer agent, is clinically approved for the treatment of nonsmall cell lung carcinoma (NSCLC) (Figure 2) [41]. On the other hand, pyrazole scaffolds have shown promising antihypertensive [42], antimicrobial [43], antidiabetic [44], antiviral [45], and anti-inflammatory activities [46].…”

Reactivity of 2‐((3‐Cyano‐4‐(4‐Fluorophenyl)‐6‐(Naphthalen‐2‐yl)Pyridin‐2‐yl)Oxy)Acetohydrazide Toward Some Reagents for Preparing a Promising Anticancer Agents and Molecular Docking Study

“…Notably, Crizotinib, a pyrazole-based anticancer agent, is clinically approved for the treatment of nonsmall cell lung carcinoma (NSCLC) (Figure 2) [41]. On the other hand, pyrazole scaffolds have shown promising antihypertensive [42], antimicrobial [43], antidiabetic [44], antiviral [45], and anti-inflammatory activities [46].…”

Reactivity of 2‐((3‐Cyano‐4‐(4‐Fluorophenyl)‐6‐(Naphthalen‐2‐yl)Pyridin‐2‐yl)Oxy)Acetohydrazide Toward Some Reagents for Preparing a Promising Anticancer Agents and Molecular Docking Study

“…Notably, Crizotinib, a pyrazole-based anticancer agent, is clinically approved for the treatment of nonsmall cell lung carcinoma (NSCLC) (Figure 2) [41]. On the other hand, pyrazole scaffolds have shown promising antihypertensive [42], antimicrobial [43], antidiabetic [44], antiviral [45], and anti-inflammatory activities [46].…”

Reactivity of 2‐((3‐Cyano‐4‐(4‐Fluorophenyl)‐6‐(Naphthalen‐2‐yl)Pyridin‐2‐yl)Oxy)Acetohydrazide Toward Some Reagents for Preparing a Promising Anticancer Agents and Molecular Docking Study

“…Notably, Crizotinib, a pyrazole-based anticancer agent, is clinically approved for the treatment of nonsmall cell lung carcinoma (NSCLC) (Figure 2) [41]. On the other hand, pyrazole scaffolds have shown promising antihypertensive [42], antimicrobial [43], antidiabetic [44], antiviral [45], and anti-inflammatory activities [46].…”